Finance
China's Bio-Thera Solutions licenses its arthritis drug to Germany's STADA
Published by Global Banking & Finance Review®
Posted on August 21, 2025
1 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on August 21, 2025
1 min readLast updated: January 22, 2026
Bio-Thera Solutions has licensed its arthritis drug BAT1806 to STADA for commercialization in Europe and other regions with payments totaling 136 million euros.
HONG KONG (Reuters) -China's Bio-Thera Solutions said on Thursday it has granted Germany's STADA Arzneimittel commercialisation rights for its arthritis drug BAT1806 in the EU, UK, Switzerland, certain Middle East and North Africa regions, and certain members of the Commonwealth of Independent States.
Upfront payment and milestone payments will total up to 136 million euros ($158.34 million), including an 8.5 million euro down payment, milestone payments up to 127.5 million euros, and a double-digit percentage of net sales as revenue sharing, the Shanghai-listed firm said in a stock exchange filing.
($1 = 0.8589 euros)
(Reporting by Hong Kong newsroom; Editing by Christopher Cushing and Muralikumar Anantharaman)
Bio-Thera Solutions has granted STADA Arzneimittel commercialization rights for its arthritis drug BAT1806 in the EU, UK, and Switzerland.
The total upfront and milestone payments for the licensing deal could reach up to 136 million euros, which includes an 8.5 million euro down payment.
BAT1806 is an arthritis drug developed by Bio-Thera Solutions, and its licensing to STADA represents a significant step in its commercialization in Europe.
Explore more articles in the Finance category
